{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:44:45Z","timestamp":1794091485191,"version":"4.8.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"abstract":"<jats:p>Motor symptoms are central to diagnosing Parkinson\u2019s disease (PD), but depression and anxiety significantly impact the prognosis and course of PD. For many PD patients, these mental health issues may be the most crucial determinants of quality of life. This study uses an interdisciplinary approach to provide an in-depth understanding of the pathogenesis, diagnostic methods, and therapeutic strategies for depression and anxiety in PD, incorporating neuroscience, psychiatry, and psychology. It aims to offer theoretical support for developing personalized medicine and precise treatments, as well as insights into future research directions. The objective of this study was to systematically sort out the research progress of PD with depression and anxiety and to provide a basis for clinical optimization of treatment strategies. Extensive searches of relevant domestic and international databases, including PubMed, Web of Science, Embase, Cochrane Library, CNKI, etc., were conducted to screen the high-quality research literature on the treatment of PD depression and anxiety in the last decade and to conduct comprehensive analyses and generalizations. Pharmacological treatments, including 5-hydroxytryptamine reuptake inhibitors, norepinephrine system agents, and dopamine agonists, showed some efficacy but with individual differences and side effects. Psychotherapies such as cognitive-behavioral therapy and group counseling improved patient mood. Neuromodulation techniques like deep brain stimulation also showed promise in refractory cases. The combined application of multiple therapeutic approaches shows good prospects in the treatment of depression and anxiety in PD, but in-depth studies are still needed to determine the optimal treatment plan while focusing on individual patient differences to achieve precise treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000041674","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:39:47Z","timestamp":1743208787000},"page":"e41674","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Advances in the study of depression and anxiety in Parkinson\u2019s disease: A review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9732-0432","authenticated-orcid":false,"given":"Zhonglong","family":"Wang","sequence":"first","affiliation":[{"name":"Shandong Daizhuang Hospital, Jining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Wei","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital, Jining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Xin","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital, Jining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9410-4532","authenticated-orcid":false,"given":"Wei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Shandong Mental Health Center Affiliated to Shandong University, Shandong, Jinan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cger.2019.09.002","article-title":"Orthostatic hypotension in Parkinson\u2019s disease.","volume":"36","author":"Palma","year":"2020","journal-title":"Clin Geriatr Med"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/mds.22611","article-title":"Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson\u2019s disease.","volume":"24","author":"Pontone","year":"2009","journal-title":"Mov Disord"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease.","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40266-022-00942-1","article-title":"Depression in patients with Parkinson\u2019s disease: current understanding of its neurobiology and implications for treatment.","volume":"39","author":"Prange","year":"2022","journal-title":"Drugs Aging"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acn3.51022","article-title":"Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson\u2019s Disease.","volume":"7","author":"Weintraub","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"117157","DOI":"10.1016\/j.jns.2020.117157","article-title":"Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson\u2019s disease.","volume":"418","author":"Kim","year":"2020","journal-title":"J Neurol Sci"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mdc3.12968","article-title":"The prevalence and determinants of neuropsychiatric symptoms in late-stage Parkinsonism.","volume":"7","author":"Hommel","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"104749","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson\u2019s disease: a systematic review and meta-analysis of 129 studies.","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/mds.22233","article-title":"Anxiety rating scales in Parkinson\u2019s disease: critique and recommendations.","volume":"23","author":"Leentjens","year":"2008","journal-title":"Mov Disord"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.22833","article-title":"Anxiety disorders in Parkinson\u2019s disease: prevalence and risk factors.","volume":"25","author":"Dissanayaka","year":"2010","journal-title":"Mov Disord"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jagp.2022.02.004","article-title":"Phenomenology of atypical anxiety disorders in Parkinson\u2019s disease: a systematic review.","volume":"30","author":"Dissanayaka","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/0891988719874130","article-title":"Prevalence of depression and anxiety in Parkinson disease and impact on quality of life: a community-based study in Spain.","volume":"33","author":"Chuquil\u00edn-Arista","year":"2020","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/brainsci10020078","article-title":"Progression of neuropsychiatric symptoms over time in an incident Parkinson\u2019s Disease Cohort (ICICLE - PD).","volume":"10","author":"Dlay","year":"2020","journal-title":"Brain Sci"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0033291715002196","article-title":"Anxiety and anxious - depression in Parkinson\u2019s disease over a 4 - year period: a latent transition analysis.","volume":"46","author":"Landau","year":"2016","journal-title":"Psychol Med"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12877-017-0666-2","article-title":"Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease.","volume":"17","author":"Cui","year":"2017","journal-title":"BMC Geriatr"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson\u2019s disease: advances.","volume":"21","author":"Weintraub","year":"2022","journal-title":"Lancet Neurol"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuroimage.2011.07.012","article-title":"Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease.","volume":"81","author":"Skidmore","year":"2013","journal-title":"Neuroimage"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.biochi.2018.11.016","article-title":"Serotonergic neurotransmission manipulation for the understanding of brain development and function: learning from Tph2 genetic models.","volume":"161","author":"Pratelli","year":"2019","journal-title":"Biochimie"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbr.2016.08.005","article-title":"Fluvoxamine maleate normalises striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression.","volume":"316","author":"Dalle","year":"2017","journal-title":"Behav Brain Res"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JCP.0b013e3181fc2ec7","article-title":"Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients.","volume":"30","author":"Ricci","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jns.2017.02.001","article-title":"Association between gene polymorphism and depression in Parkinson\u2019s disease: a case-control study.","volume":"375","author":"Zheng","year":"2017","journal-title":"J Neurol Sci"},{"key":"R23-20250328","doi-asserted-by":"crossref","first-page":"101840","DOI":"10.1016\/j.arr.2022.101840","article-title":"Neurobiology of depression in Parkinson\u2019s disease: insights into epidemiology, molecular mechanisms and treatment strategies.","volume":"85","author":"Ahmad","year":"2023","journal-title":"Ageing Res Rev"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/089198879901200202","article-title":"Depression and anxiety in Parkinson\u2019s disease: possible effect of genetic variation in the serotonin transporter.","volume":"12","author":"Menza","year":"1999","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.28404","article-title":"Neuroimaging of anxiety in Parkinson\u2019s disease: a systematic review.","volume":"36","author":"Carey","year":"2021","journal-title":"Mov Disord"},{"key":"R26-20250328","doi-asserted-by":"crossref","first-page":"e1500301","DOI":"10.1126\/sciadv.1500251","article-title":"Prefrontal inputs to the amygdala instruct fear extinction memory formation.","volume":"1","author":"Bukalo","year":"2015","journal-title":"Sci Adv"},{"key":"R27-20250328","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","article-title":"Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease.","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov Disord"},{"key":"R28-20250328","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fncel.2016.00293","article-title":"Early degeneration of both dopaminergic and serotonergic axons - a common mechanism in Parkinson\u2019s Disease.","volume":"10","author":"Grosch","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"R29-20250328","first-page":"3853","article-title":"Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson\u2019s disease.","volume":"20","author":"Wang","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R30-20250328","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp-2017-316193","article-title":"Serotonin transporter binding and anxiety symptoms in Parkinson\u2019s disease.","volume":"89","author":"Joling","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R31-20250328","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14802\/jmd.18051","article-title":"Pseudobulbar affect in Parkinsonian disorders: a review.","volume":"12","author":"Hakimi","year":"2019","journal-title":"J Mov Disord"},{"key":"R32-20250328","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson\u2019s disease in primary care: a case-control study.","volume":"14","author":"Schrag","year":"2015","journal-title":"Lancet Neurol"},{"issue":"Suppl. 1","key":"R33-20250328","first-page":"125s","article-title":"Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke.","volume":"55","author":"Shinagawa","year":"2001","journal-title":"Biomed Pharmacother"},{"key":"R34-20250328","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mds.21866","article-title":"A validation study of depressive syndromes in Parkinson\u2019s disease.","volume":"23","author":"Starkstein","year":"2008","journal-title":"Mov Disord"},{"key":"R35-20250328","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000002898","article-title":"Detecting depression in Parkinson disease: a systematic review and meta-analysis.","volume":"87","author":"Goodarzi","year":"2016","journal-title":"Neurology"},{"key":"R36-20250328","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2019.09.012","article-title":"Depression and anxiety in Parkinson disease.","volume":"36","author":"Ray","year":"2020","journal-title":"Clin Geriatr Med"},{"key":"R37-20250328","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/mds.26522","article-title":"Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson\u2019s disease.","volume":"31","author":"Martinez-Martin","year":"2016","journal-title":"Mov Disord"},{"key":"R38-20250328","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11065-015-9302-0","article-title":"Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson\u2019s disease: a meta-analysis.","volume":"25","author":"Combs","year":"2015","journal-title":"Neuropsychol Rev"},{"key":"R39-20250328","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.parkreldis.2015.04.018","article-title":"Antidepressive treatments for Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"21","author":"Bomasang-Layno","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"R40-20250328","doi-asserted-by":"crossref","first-page":"e79510","DOI":"10.1371\/journal.pone.0079510","article-title":"A meta-analysis of randomized placebo-controlled treatment trials for depression and anxiety in Parkinson\u2019s disease.","volume":"8","author":"Troeung","year":"2013","journal-title":"PLoS One"},{"key":"R41-20250328","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881113478282","article-title":"Antidepressants for depression in Parkinson\u2019s disease: systematic review and meta-analysis.","volume":"27","author":"Rocha","year":"2013","journal-title":"J Psychopharmacol"},{"key":"R42-20250328","doi-asserted-by":"crossref","first-page":"e1764","DOI":"10.1212\/WNL.0000000000009292","article-title":"Telephone-based cognitive behavioural therapy for depression in Parkinson disease: a randomized controlled trial.","volume":"94","author":"Dobkin","year":"2020","journal-title":"Neurology"},{"key":"R43-20250328","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/mds.28548","article-title":"Innovating Parkinson\u2019s care: a randomized controlled trial of telemedicine depression treatment.","volume":"36","author":"Dobkin","year":"2021","journal-title":"Mov Disord"},{"key":"R44-20250328","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/s00415-016-8160-x","article-title":"Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson\u2019s disease.","volume":"263","author":"Shin","year":"2016","journal-title":"J Neurol"},{"key":"R45-20250328","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/08919887211018267","article-title":"Mood disorders and anxiety in Parkinson\u2019s disease: current concepts.","volume":"34","author":"Lintel","year":"2021","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R46-20250328","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.clinph.2014.05.021","article-title":"Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS).","volume":"125","author":"Lefaucheur","year":"2014","journal-title":"Clin Neurophysiol"},{"key":"R47-20250328","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1176\/jnp.10.2.187","article-title":"Effectiveness of ECT in patients with Parkinsonism.","volume":"10","author":"Moellentine","year":"1998","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R48-20250328","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mds.28335","article-title":"Electroconvulsive therapy for Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"36","author":"Takamiya","year":"2021","journal-title":"Mov Disord"},{"key":"R49-20250328","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3171\/2016.11.JNS16715","article-title":"Deep brain stimulation for Parkinson\u2019s disease: meta-analysis of results of randomised trials at varying lengths of follow-up.","volume":"128","author":"Mansouri","year":"2018","journal-title":"J Neurosurg"},{"key":"R50-20250328","first-page":"e2232","article-title":"Subthalamic and pallidal deep brain stimulation for Parkinson\u2019s disease.","volume":"10","author":"Negida","year":"2018","journal-title":"Cureus"},{"key":"R51-20250328","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.brs.2016.12.014","article-title":"The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson\u2019s disease.","volume":"10","author":"Birchall","year":"2017","journal-title":"Brain Stimul"},{"key":"R52-20250328","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.sleep.2021.03.035","article-title":"The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson\u2019s disease: a systematic review and meta-analysis of randomised controlled trials.","volume":"83","author":"Lin","year":"2021","journal-title":"Sleep Med"},{"key":"R53-20250328","doi-asserted-by":"crossref","first-page":"e0181515","DOI":"10.1371\/journal.pone.0181515","article-title":"Effectiveness of physical activity on patients with depression and Parkinson\u2019s disease: a systematic review.","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"R54-20250328","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson\u2019s disease: consequences of l-DOPA treatment.","volume":"35","author":"Eskow","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"R55-20250328","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial.","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"R56-20250328","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study.","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"R57-20250328","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"R58-20250328","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s11130-023-01103-4","article-title":"Naringenin, a functional food component, improves motor and non-motor symptoms in animal model of Parkinsonism induced by rotenone.","volume":"78","author":"Madiha","year":"2023","journal-title":"Plant Foods Hum Nutr"},{"key":"R59-20250328","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/17425255.2020.1750596","article-title":"Pharmacokinetics and pharmacodynamics of levodopa\/carbidopa cotherapies for Parkinson\u2019s disease.","volume":"16","author":"M\u00fcller","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R60-20250328","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1517\/14656566.2012.736490","article-title":"A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson\u2019s disease.","volume":"13","author":"Bonuccelli","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R61-20250328","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2017.01.066","article-title":"Effects of duloxetine on motor and mood symptoms in Parkinson\u2019s disease: an open-label clinical experience.","volume":"375","author":"Nishijima","year":"2017","journal-title":"J Neurol Sci"},{"key":"R62-20250328","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson\u2019s disease.","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"R63-20250328","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JPD-171143","article-title":"Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease.","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"R64-20250328","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","article-title":"Depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.","volume":"111","author":"Da Silva","year":"2008","journal-title":"J Affect Disord"},{"key":"R65-20250328","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2174\/1570159X20666220915091022","article-title":"Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson\u2019s disease.","volume":"21","author":"Jing","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"R66-20250328","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","article-title":"Effect of istradefylline on mood disorders in Parkinson\u2019s disease.","volume":"396","author":"Nagayama","year":"2019","journal-title":"J Neurol Sci"},{"key":"R67-20250328","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s00213-014-3454-0","article-title":"Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.","volume":"231","author":"Yamada","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"R68-20250328","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainresbull.2020.12.011","article-title":"Ketamine reverses short-term memory impairment and depressive-like behaviour in animal model of Parkinson\u2019s disease.","volume":"168","author":"Vecchia","year":"2020","journal-title":"Brain Res Bull"},{"key":"R69-20250328","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.expneurol.2017.11.009","article-title":"Pioglitazone reduces mortality, prevents depressive-like behaviour, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson\u2019s disease in rats.","volume":"300","author":"Bonato","year":"2018","journal-title":"Exp Neurol"},{"key":"R70-20250328","doi-asserted-by":"crossref","first-page":"3472032","DOI":"10.1155\/2016\/3472032","article-title":"Melatoninergic system in Parkinson\u2019s disease: from neuroprotection to the management of motor and nonmotor symptoms.","volume":"2016","author":"Mack","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"R71-20250328","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/practneurol-2017-001650","article-title":"). What a neurologist should know about depression in Parkinson\u2019s disease.","volume":"17","author":"Timmer","year":"2017","journal-title":"Pract Neurol"},{"key":"R72-20250328","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1037\/0278-6133.23.6.599","article-title":"Is it beneficial to involve a family member? A meta-analysis of psychosocial interventions for chronic illness.","volume":"23","author":"Martire","year":"2004","journal-title":"Health Psychol"},{"key":"R73-20250328","first-page":"3576","article-title":"Clinical analysis of anxiety disorder misdiagnosed as Parkinson\u2019s disease in elderly people.","volume":"16","author":"Yang","year":"2015","journal-title":"Chin J Gen Med"},{"key":"R74-20250328","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","article-title":"Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations.","volume":"130","author":"Regensburger","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"R75-20250328","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/da.22043","article-title":"Let\u2019s get physical: a contemporary review of the anxiolytic effects of exercise for anxiety and its disorders.","volume":"30","author":"Asmundson","year":"2013","journal-title":"Depress Anxiety"},{"key":"R76-20250328","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/jnnp-2013-306907","article-title":"Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease using an MRI-guided and MRI-verified approach.","volume":"85","author":"Aviles-Olmos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R77-20250328","doi-asserted-by":"crossref","first-page":"372","DOI":"10.20344\/amp.4928","article-title":"Depression and anxiety following deep brain stimulation in Parkinson\u2019s disease. Systematic review and meta-analysis.","volume":"27","author":"Couto","year":"2014","journal-title":"Acta Med Port"},{"key":"R78-20250328","first-page":"670","article-title":"Clinical characteristics and related factors of rapid eye movement sleep behaviour disorder in patients with Parkinson\u2019s disease.","volume":"41","author":"Huang","year":"2015","journal-title":"Chin J Neuropsychiatr Disord"},{"key":"R79-20250328","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-b inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future.","volume":"12","author":"Tan","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"R80-20250328","doi-asserted-by":"crossref","first-page":"eabe7099","DOI":"10.1126\/scitranslmed.abe7099","article-title":"Slow-wave sleep affects synucleinopathy and regulates proteostatic processes in mouse models of Parkinson\u2019s disease.","volume":"13","author":"Morawska","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:45:04Z","timestamp":1743363904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041674","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}